Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020; 383: 207-217.
Published: 16th September 2020
Authors: Claiborne Johnston S, Amarenco P, Denison H, Evans SR, Himmelmann A, James S et al.
A total of 11,016 patients were randomized. The risk of death or stroke within 30 days was lower in the ticagrelor with aspirin group (5.5% versus 6.6 per cent for aspirin alone, P=0.02). The rate of disability at 30 days was similar in the two groups.Pubmed Link
You may also be interested in
Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994-2004.
Authors: Bonaca MP, Bauersachs RM, Anand S, Debus ES, Nehler MR, Patel MR et al.
Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet 2020; 395: 1487-1495.
Authors: Chiarito M, Sanz-Sanchez J, Cannata F, Cao D, Sturla M, Panico C et al.
Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. The COMPASS Trial. Circulation 2019; 140: 529-537
Authors: Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK et al.
No clinical benefit of intramuscular delivery of bone marrow-derived mononuclear cells in nonreconstructable peripheral arterial disease: results of a phase-III randomized-controlled trial. Ann Surg 2018; 268: 756-761.
Authors: Lindeman J, Zwaginga J, Kallenberg-Lantrua G, van Wissen RC, Schepers A, van Bockel HJ et al.
A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease. J Vasc Surg 2018; 67: 1922-1932.
Authors: Beiswenger AC, Jo A, Harth K, Kumins NH, Shishehbor MH, Kashyap VS et al.
Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379: 215-225.
Authors: Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ et al.
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018; 392: 387–399.
Authors: Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC et al.
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229.
Authors: Anand S, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P et al.
Efficacy and safety of aspirin in patients with peripheral vascular disease: an updated systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2017; 12: e0175283.
Authors: Mahmoud AN, Elgendy AY, Rambarat C, Mahtta D, Elgendy IY, Bavry AA et al.
Evaluation of cell therapy on exercise performance and limb perfusion in peripheral artery disease. Circulation. 2017; 135: 1417-1428.
Authors: Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC et al.
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-1330.
Authors: Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al.
Efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease Fontaine stage IV: results of a placebo-controlled randomized multicenter trial (ESPECIAL). Eur J Vasc Endovasc Surg 2017; 53: 559-566.
Authors: Lawall H, Pokrovsky A, Checinski P, Ratushnyuk A, Hamm G, Randerath O et al.